Asia-Pacific Antifungal Drugs Market:
By Product Type (Azoles, Allylamines, Echinocandins, Polyenes and Others), By Dosage Forms (Solutions, Tablets & Capsules, Ointments & Creams, Powders, and Others), By Application (Aspergillosis, Candidiasis, Dermatophytosis, and Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Drug Stores), and Country (Japan, China, India, Australia & New Zealand, ASEAN, South Korea, and Rest of Asia-Pacific) – Market Estimation, Dynamics, Country Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Asia-Pacific Antifungal Drugs Market Report Description:
Asia-Pacific antifungal drugs market report gives the comprehensive outlook on antifungal drugs prescription pattern across the region with special emphasis on key countries such as Japan, China, India, Australia & New Zealand, Indonesia, Thailand, Vietnam, Philippines, Malaysia, and South Korea. The report on antifungal drugs market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application, the dosage form, and country. This report presents antifungal drugs market dynamics elaborately to identify the current market trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the antifungal drugs market report includes the competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed antifungal drugs market to better equip clients with possible investment opportunities across the regions (Country Investment Hot-Spots) and market unmet needs. Key stakeholders of the Asia-Pacific Antifungal Drugs Market report include raw material suppliers, manufacturers, marketers, hospitals, physician offices, policymakers, and healthcare service providers, who are engaged in usage and advocacy of antifungal drugs.
Asia-Pacific Antifungal drugs Market:
Asia-Pacific antifungal drugs market was valued at US$ 2,500 Mn in 2016 and poised to grow around 4% CAGR over 2017-2023.
Competition Assessment
Key players profiled in the Asia-Pacific antifungal drugs market include:
- Astellas Pharma, Inc. (Japan)
- Bayer AG (Germany)
- Enzon Pharmaceuticals, Inc. (U.S.)
- GlaxoSmithKline Plc. (U.K.)
- Merck & Co., Inc. (U.S.)
- Novartis AG (Switzerland)
- Pfizer, Inc. (U.S.)
- Sanofi (France)
Players in the Asia-Pacific antifungal drugs market are entering into partnerships and collaborations to garner larger market share
Key Features of the Report:
- The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Detailed Segmentation
By Product Type
- Azoles
- Allylamines
- Echinocandins
- Polyenes
- Others
By Dosage Forms
- Solutions
- Tablets & Capsules
- Ointments & Creams
- Powders
- Others
By Application
- Aspergillosis
- Candidiasis
- Dermatophytosis
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Geography
- Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
